Pharmaceutical company Indivior has appointed four new non-executive directors to its board.

Juliet Thompson, Joanna Le Couilliard and Mark Stejbach join as independent NEDs, with Jerome Lande, a partner at Indivior shareholder Scopia, joining as a NED.

Thompson is a former investment banker who has spent her career advising pharmaceutical companies. She currently chairs the audit committees of Novacyt and Vectura, and is also a non-executive director of Organox. She will be a member of the audit and nomination and governance committees, and will be appointed to chair the audit committee following the 2021 AGM in May.

Le Couilliard was formerly part of GlaxoSmithKline’s global pharmaceuticals leadership team and chief operating officer at the BMI group of UK private hospitals. She will be a member of the audit and remuneration committees.

Stejbach most recently served as senior vice president and chief commercial officer at Alkermes. He will be a member of the audit and science and policy committees.

Meanwhile, Lande is head of special situations investments at Scopia Capital Management. He will join the audit and nomination and governance committees.

All the new NEDs will stand for election by shareholders at the 2021 AGM.

In other board changes at the company, Graham Hetherington will assume the role of chair of the nomination and governance committee following the conclusion of the 2021 AGM, taking over from current chair Lorna Parker, who will be stepping down from the board upon the appointment of a further independent NED candidate.

Daniel Tassé, current senior independent director, will not stand for re-election at the 2021 AGM and will stand down at the conclusion of that meeting. He will be replaced as senior independent director by Dan Phelan.

Chair Graham Hetherington said: “We are pleased to welcome the new NEDs to the board and unanimously recommend that shareholders vote in favour of their appointment at the forthcoming 2021 Annual General Meeting of shareholders on 6 May 2021.

“Indivior’s board and leadership team are committed to engaging actively with shareholders to better understand their views and we fully support and look forward to Jerome’s perspectives as a representative of our largest shareholder.”